Pharmacokinetics and bioequivalence of eperisone hydrochloride tablet in healthy subjects

Yaoxue Xuebao

Volumn 39, Issue 4, 2004, Pages 309-311

  Wei, Xin ^a   Ding, Li ^a   Gao, Jia Min ^a   Li, Jun ^a   Zhang, Sheng Qiang ^a   Shen, Jian Ping ^b   Zhang, Yin Di ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bioequivalence; Eperisone hydrochloride; HPLC ESI MS; Pharmacokinetics

Indexed keywords

BUFLOMEDIL; EPERISONE; PROPIOPHENONE DERIVATIVE;

ARTICLE; BIOEQUIVALENCE; CALIBRATION; CONTROLLED STUDY; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; ION MONITORING; MASS SPECTROMETER; NORMAL HUMAN; RANDOMIZATION; SEPARATION TECHNIQUE; STANDARD; TABLET; ADULT; ELECTROSPRAY MASS SPECTROMETRY; MALE; PHARMACOKINETICS;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; PROPIOPHENONES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 4444350438     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Fu CM, Li B, Guo RC. Determination of eperisone hydrochloride tablets by high performance liquid chromatography [J]. Chin J Mod Appl Pharm, 2001,18(1):57-59.
2. Song YH, Shi AX, Song L, et al. Bioequivalence of eperisone hydrochloride tablets in healthy volunteers [J]. Chin Pharm J, 2000,35(3):186-189.
3. State Pharmacopoeia Committee of the People's Republic of China. Pharmacopoeia of the People's Republic of China. 2000 Ed. Part II. Beijing: Chemical Industry Press. Addendum: 195.
4. Yang J, Wang GJ, Liu XQ, et al. Development of Bioavailability Program Package 2.0 [J]. Chin J Clin Pharmacol, 2003, 19(2):125-127.
5. Takamatsu T, Yamazaki K, Kayano M, et al. Determination of eperisone in human plasma by gas chromatography-mass spectrometry [J]. J Chromatogr B, 1992, 584:261-266.